The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. - sprookjes - yvandenbroek - TriplyDB

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

http://www.wikidata.org/entity/Q35454299

about

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy Evolving treatment paradigms for chemotherapy-induced nausea and vomiting Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials.The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Evaluating the various phases of cisplatin-induced emesis in rats.Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.Netupitant PET imaging and ADME studies in humans.Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomiz Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery.Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy Treatment of Nausea and Vomiting During Chemotherapy.A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.Measuring the nausea-to-emesis continuum in non-human animals: refocusing on gastrointestinal vagal signaling Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron.Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis.Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew).Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.A randomized, double-blind trial evaluating the efficacy of palonosetron with total intravenous anesthesia using propofol and remifentanil for the prevention of postoperative nausea and vomiting after gynecologic surgery.A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period.

P2860

Q26748524-7D2F78EA-9A00-482F-8B3B-D4CF694F6E7A Q26783229-32279078-5D3D-4BB8-AB13-4F7E3D7DD5C8 Q27024463-048EDCBB-404C-4D36-A876-4F76FD552815 Q28084970-9069A937-B3D5-403B-8BEA-D66E22C6AB83 Q33735025-8E78A21A-EF20-4AD2-8BA8-8E38D6B78151 Q33805465-EE5781B9-17AB-4CE9-9620-986D312E919F Q34166946-D72709E6-3FE8-443D-905F-3F0E63FED3EA Q34293135-F7E0A112-62B2-4C3E-A5A3-9E54093C92C5 Q34348084-619D0591-CC5F-41F2-841C-C2B5E0249456 Q34377521-0F19B9CC-BBA8-4832-B67E-BD02028CFAAE Q34582576-BEBE9C97-96D3-4F1F-8EA4-681BC6C08C66 Q35028927-49F8514F-014E-4003-B53C-A292233B215B Q35904224-414BB3B8-F432-4FB9-B9AE-B68FAF9118B3 Q36004950-C5D3A175-F5F0-4710-BD2A-F1FD9D89D60A Q36354684-2ED9E11D-35EA-4A5F-838A-EC1B947DFA63 Q36524349-F5507B0F-FBE3-451C-B261-456F4F0AB549 Q36636930-ADE0668D-6FE6-450D-A407-3C656E89C1A1 Q37161371-354FA429-448F-4ABA-BBF9-01035BE2D37E Q37503489-71777C81-07BC-4E71-A2CF-9B4F6BC9F51F Q37551843-6F82AA32-FACD-4192-953E-44DD28D3D308 Q37559641-F02FA07A-6445-4885-9E3E-417704346A36 Q37609798-D772E496-6ABC-4FC5-AF5A-A21EEDD7C8CD Q38132238-5FA340FA-9302-4F0A-B8BE-30B47996CB2A Q38215005-0E597EA6-E5E2-494B-A815-E010782B89B6 Q38264147-CEC8811B-BF3D-4F95-9F3C-2F1ED93CD7E1 Q38443441-AB6CCE76-CFBF-47EA-B318-BDBBB7C9D712 Q38497106-CF302D12-7A87-4A82-AFBD-CDB989FF0CFA Q38571176-66AFB388-4E15-4030-99E4-36760BAC9F5F Q38650400-31410E2D-E48F-4A82-9C0F-AC32D48E31C2 Q38676345-F35C8312-02B3-447A-839D-C6EF3D010538 Q38980779-985A72A1-6F85-4677-B4F8-8CE91924D83F Q39173196-2B64599A-3414-4B46-9E54-9ACAA8A1F4BC Q39213490-E6A5DE61-1229-44B8-A9E4-E1CACC033A52 Q40978787-9F66E959-D3EF-40D5-A439-65A8890E6395 Q41385767-96A1A48D-786D-4990-B4FF-45FAB3AF3B0C Q42107538-9197754F-3E46-48CA-B4BD-C496FBF10996 Q42201240-EE739EB3-ED5D-4BFB-9F9D-C4BE07BF563B Q43581868-771F0156-C7A7-4E9B-B78E-DEBA169DF2A8 Q47386798-095D28D0-ABF9-4FE1-B779-84BF0E2C5D18 Q47841681-8AAAE59B-42D1-47DF-939D-474126464C39

P2860

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

http://www.wikidata.org/entity/Q35454299

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@ast

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@en

type

label

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@ast

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@en

prefLabel

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@ast

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@en

P1433

Q35454299-027C48DC-B36C-4E56-9D5B-03D95663597F

P1476

Q35454299-B6683F09-6539-4332-80F3-FD276E03F18F

P2093

Q35454299-0043651E-3C91-4DAE-A81A-C135F6D78C6D

Q35454299-0634C526-3FF9-4095-963F-114E178CEA16

Q35454299-5C87304A-93B9-409C-8059-909AC0726504

Q35454299-7D3E52DA-7CE2-49CD-93A3-D5E221489D60

Q35454299-86F9285F-0706-48AF-BCF2-FE723A227EEE

Q35454299-B3B43463-14E9-4977-A7FD-DB51C67BD9EB

Q35454299-B4169585-6390-4343-8632-9B09064DA422

Q35454299-B5F5BD02-B4F5-409B-A072-860A120CC978

Q35454299-CE0B2550-B449-4D3B-97F5-60220220CDD1

Q35454299-FB90100D-F37C-45B5-B3A8-29E8FE6B6787

P2860

Q35454299-1B81A1C7-399F-45ED-B525-92C970795CEC

Q35454299-203AA52E-3DFE-4FE8-86BA-1BBAA2ADA225

Q35454299-275E0EDC-94E8-408B-AF87-743C93C7DBFE

Q35454299-2768E29F-1EAD-4C99-B0E7-C76876430860

Q35454299-36B3B306-3E2E-4E9D-A433-498BDF3A756B

Q35454299-387D6ED4-F179-4063-A4FE-0FD61C63EB95

Q35454299-423A950B-51A0-4CC2-B32A-CC50B09C9B2E

Q35454299-5098F7B3-204A-40C1-9474-CFAB737DCFA1

Q35454299-69141854-1E0F-442E-B59B-4EDF2AB0A92E

Q35454299-826E84C0-4434-45D3-B794-364CBE75CDBF

P304

Q35454299-1BAA5596-2291-400A-B71A-E592F2FA144C

P31

Q35454299-66FC5309-F7B3-4A5D-86AF-61F1F92A6031

P356

Q35454299-777A7651-467C-4BAB-821B-3744464B34C8

P407

Q35454299-824EA251-2CB5-4806-A1F3-2C17212A3218

P433

Q35454299-41FD2815-8AC0-47F8-8617-138E66B88F86

P478

Q35454299-31FBDA76-E23E-4E91-A31B-AE6DD8498D98

P577

Q35454299-3DA40E55-E4AF-447F-AD70-B0F1A0DD80AE

P5875

Q35454299-39D66C87-C2AE-4D0C-834A-F84F8C949821

P698

Q35454299-1C7F63B0-B9FC-498F-9059-9A904F4D9361

P932

Q35454299-BDD8F39F-A072-4D3F-BAB8-821D9A5871B6

P356

JPET.110.166181

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

The antiemetic 5-HT3 receptor ...... esponses in vitro and in vivo.

@en

P2093

Ajit G Thomas

http://www.w3.org/2001/XMLSchema#string

Barbara S Slusher

http://www.w3.org/2001/XMLSchema#string

Camilo Rojas

http://www.w3.org/2001/XMLSchema#string

Claudio Pietra

http://www.w3.org/2001/XMLSchema#string

Jesse Alt

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Marigo Stathis

http://www.w3.org/2001/XMLSchema#string

Sergio Cantoreggi

http://www.w3.org/2001/XMLSchema#string

Silvia Sebastiani

http://www.w3.org/2001/XMLSchema#string

Ying Li

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.

Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.

An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors.

Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption ("pica") in rats.

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons.

P304

362-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.110.166181

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

335

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45720838

http://www.w3.org/2001/XMLSchema#string

P698

20724484

http://www.w3.org/2001/XMLSchema#string

P932

3202469

http://www.w3.org/2001/XMLSchema#string